Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.
By A. Prøven, S. Gabriel, C. Orces, W. O'Fallon, G. Hunder. Arthritis & Rheumatism, 2003
603 citations recorded by the source corpus.
Subfields: Genetics, Pulmonary and Respiratory Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/18b018d29baeb2e1b1d779b56d5ee552165ea8c6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- T. Hauser
- C. Mukhtyar
- P. Merkel
- L. Guillevin
- David Steven Scott
- D. Jayne
- W. Gross
- J. Witter
Citations in the corpus
- EULAR recommendations for the management of large vessel vasculitis (2008, background): “[Level of evidence 3, Strength of recommendation C] Early intensive therapy with high-dose glucocorticoid induces remission in patients with large vessel vasculitis (19, 52, 53).”
- Trial of Tocilizumab in Giant‐Cell Arteritis (2017, neutral): “Injury, poisoning, or procedural complication 3 (3) 1 (2) 1 (2) 0”